What Happened
The Food and Drug Administration on November 9, 2026 issued a Drug Safety Communication requiring every holder of an approved glucagon-like peptide-1 receptor agonist (GLP-1 RA) application to add information about non-arteritic anterior ischemic optic neuropathy (NAION) to the Warnings and Precautions section of its labeling.
The requirement is class-wide: twelve approved products, from Victoza and Trulicity through Ozempic, Rybelsus, Wegovy, Mounjaro and Zepbound, plus Foundayo (orforglipron), the oral GLP-1 approved this year. FDA said NAION cases have been reported for all marketed GLP-1 RAs.
It closes a gap that had grown awkward. European, UK and Australian labels have carried NAION language since 2025, when the European Medicines Agency concluded the condition was a "very rare" side effect of semaglutide medicines. The U.S. label did not. PepsReview reported in October that the review was pending while attorneys built litigation around that absence.
The Evidence FDA Weighed
FDA did not rely on adverse-event reports alone, and said so: NAION risk factors overlap heavily with conditions GLP-1 patients commonly have.
It ran a meta-analysis of 126 randomized trials covering 134,253 patients and 288,879 person-years. Fifteen probable NAION events surfaced — ten in patients on a GLP-1 RA, five on placebo, none on a non-GLP-1 glucose-lowering drug. That is 6.4 cases per 100,000 person-years on treatment versus 3.8 on comparator.
A retrospective cohort in FDA's Sentinel commercial network told a less flattering story. Among adults with type 2 diabetes starting treatment between 2019 and 2024, incidence ran 30 to 32 per 100,000 person-years on GLP-1 RAs, 31 on SGLT-2 inhibitors and 26 on DPP-4 inhibitors. Against SGLT-2 inhibitors the hazard ratio was 1.19, with a confidence interval of 0.91-1.54 — not statistically significant. Against DPP-4 inhibitors it was 1.43 (1.02 to 2.01), which was.
Animal data turned up no plausible mechanism. FDA required the warning anyway.
Who Is Affected
Prescribers of every GLP-1 RA, the labelers amending prescribing information, and the millions of patients who are the audience for the new language. Compounded semaglutide and tirzepatide sold outside the approval framework are not covered by a labeling requirement — the gap enforcement letters keep trying to close from the other direction.
Timeline
- July 2024 — Hathaway et al. publish a JAMA Ophthalmology study linking semaglutide to NAION risk.
- March 2025 — FDA lists NAION as a potential safety signal.
- June 2025 — EMA concludes NAION is a very rare side effect; European labeling follows.
- September 2026 — the federal NAION litigation passes 216 consolidated cases.
- October 2026 — U.S. labels still carry no NAION warning.
- November 9, 2026 — FDA requires the warning across the class.
What This Means for Researchers
The two datasets point in different directions, and FDA did not pretend otherwise. A meta-analysis built on 15 events across 134,000 patients is statistically fragile; the Sentinel comparison against SGLT-2 inhibitors failed significance while the DPP-4 comparison passed it. The agency effectively concluded that the signal is consistent enough across independent designs to warrant disclosure — not that causality is settled.
The practical lesson is that class-wide labeling can precede mechanistic understanding. No mechanism was found in animal models, yet the warning is now mandatory.
How to Verify Your Peptides
Documentation matters more than vendor claims. Our guide to how testing works explains the analytical chain, and identity, purity and fill-weight testing covers what a certificate of analysis should report.
Safe Alternatives
Approved GLP-1 therapies with full labeling are covered in our peptide reference library, including semaglutide and tirzepatide. Our vendor directory lists suppliers with documented testing practices.
Sources
Regulatory announcements — FDA Drug Safety Communication, November 9, 2026. Peer-reviewed literature — Hathaway JT et al., JAMA Ophthalmology, August 2024. Industry reports.